Versant Ventures closed on its newest fund, Versant Venture Capital VI, with $400 million it plans to invest in 20 to 25 biotechnology companies in the U.S., Canada and Europe. The first investment is expected in the first quarter of 2017.
In the first half of 2016, investors were watching the Pfizer-Allergan merger deal, which was scuttled in April by the U.S. Treasury Department. Part of the fascination, besides the fact it would have created the largest pharmaceutical company in the world, was over how in about seven years Allergan’s CEO Brent Saunders had gone from heading the consumer health division at Schering-Plough to being the chief-executive-in-waiting for the biggest pharma company on the planet.
There are plenty of “brand name” biotech companies out there that everyone interested in biopharma knows about — Shire, Gilead Sciences, Genentech, Biogen and so on — but there are several smaller biotech companies that investors may not have heard of that are worth checking out. Keith Speights, writing for The Motley Fool, takes a look at three.
Drugs recently approved around the world to fight cancer increased patients’ overall survival, but benefits vary depending on the drug, a new study shows.